[Oxaliplatin -- A 10-Year Trajectory].
Oxaliplatin(Elplat(®)iv infusion solution)is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.
Division of Gastrointestinal Surgery, Dept. of Surgery, Graduate School of Medicine, Kobe University.
Shingo
S
Kanaji
Eiji
E
Oki
Hiroshi
H
Saeki
Hiroyuki
H
Kitao
Yoshihiko
Y
Maehara
Yoshihiro
Y
Kakeji
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin